- Home
- EWCZ vs TSHA Comparison
EWCZ vs TSHA Comparison
Compare EWCZ & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EWCZ | TSHA |
|---|---|---|
| Founded | 2004 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.5M | 1.2B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EWCZ | TSHA |
|---|---|---|
| Price | $3.75 | $5.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $5.50 | ★ $10.22 |
| AVG Volume (30 Days) | 331.9K | ★ 3.6M |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.45 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $211,264,000.00 | $6,310,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.62 | N/A |
| P/E Ratio | $14.33 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.72 | $1.05 |
| 52 Week High | $7.60 | $5.95 |
Technical Indicators
Market Signals| Indicator | EWCZ | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 44.08 | 59.24 |
| Support Level | $3.67 | $5.22 |
| Resistance Level | $4.33 | $5.95 |
| Average True Range (ATR) | 0.18 | 0.32 |
| MACD | -0.03 | 0.08 |
| Stochastic Oscillator | 12.03 | 75.26 |
Price Performance
Historical ComparisonAbout EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.